When a 'routine' TURBT is not routine: Lessons from SEER-medicare [0.03%]
当"TURBT常规" 并非真正常规时的教训——来自SEER- medicare的启示
Kamil Malshy,Edward M Messing
Kamil Malshy
Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank [0.03%]
来自英国生物样本库的证据：膀胱癌的遗传易感性和环境危险因素
Laura Bukavina,Ilaha Isali,Sneha Parekh et al.
Laura Bukavina et al.
Purpose: This study aims to identify specific genotypes within the UK Biobank (UKB) cohort contributing to a genetic predisposition for bladder cancer (UBC). It highlighted the impact of environmental exposures and the br...
Impact of lymphovascular invasion and histological variants on BCG-treated high-grade NMIBC prognosis [0.03%]
淋巴管侵犯和组织学亚型对BCG治疗失败的高危NMIBC预后的影响分析
Ali Nebioğlu,Mert Başaranoğlu,Murat Bozlu et al.
Ali Nebioğlu et al.
Purpose: This study aimed to evaluate the impact of lymphovascular invasion (LVI) and histologic subtypes on prognosis following Bacillus Calmette-Guérin (BCG) therapy in high-grade non-muscle invasive bladder cancer (NM...
Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer [0.03%]
基于基因表达的膀胱癌淋巴结转移预测模型的效果评估
Hafdís Birta Johansson,Fredrik Liedberg,Carina Bernardo et al.
Hafdís Birta Johansson et al.
Background: The presence of cancer in pelvic lymph nodes removed during radical surgery for muscle-invasive bladder cancer (MIBC) is a key determinant of patient outcome. It would be beneficial to predict node status preoperatively to tailo...
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management [0.03%]
膀胱小细胞癌：发病机制、临床表现及治疗进展的文献复习
Nicholas I Simon,Andre R Kydd,Dilara Akbulut et al.
Nicholas I Simon et al.
Small cell carcinoma of the bladder (SCCB) is a rare, aggressive malignancy that accounts for less than 1% of all bladder cancers. In this report, we highlight the clinical manifestations of SCCB (including epidemiology, cystoscopic and ima...
Tine Ginnerup Andreasen,Trine Strandgaard,Line Raaby et al.
Tine Ginnerup Andreasen et al.
Background: The recommended treatment for high-risk non-muscle invasive bladder cancer (NMIBC) is intravesical instillations of Bacillus Calmette-Guérin (BCG). Despite completing BCG therapy, up to 40% of patients experi...
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer [0.03%]
高危非肌层浸润性膀胱癌的新兴保膀胱疗法
Clarissa M Gurbani,Yew-Lam Chong,Zhen Wei Choo et al.
Clarissa M Gurbani et al.
Bladder cancer (BC) is a significant global health concern, with non-muscle invasive bladder cancer (NMIBC) comprising 75% of cases at diagnosis. High-risk NMIBC (HR-NMIBC) poses a significant therapeutic challenge due to its high recurrenc...
The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC) [0.03%]
经尿道膀胱肿瘤电切(TURBT)联合三联疗法治疗肌层浸润性膀胱癌的意义
Chris Ho-Ming Wong,Ivan Ching-Ho Ko,David Ka-Wai Leung et al.
Chris Ho-Ming Wong et al.
Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical cystectomy for select patients with muscle-i...
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC [0.03%]
诱导治疗后高危NMIBC首次监测中蓝光膀胱镜和额外手术评估的作用
Ian M McElree,Ryan L Steinberg,Sarah L Mott et al.
Ian M McElree et al.
Background: During surveillance of high-risk non-muscle invasive bladder cancer (HR-NMIBC), occult disease can be missed by standard cystoscopy. Objective...
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer [0.03%]
上尿路尿路上皮癌术前化疗灌注治疗
Edward M Messing,Kamil Malshy
Edward M Messing